Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

U.S. Surgeon General Vivek Murthy said Friday that two alcoholic drinks a day increases the risk for seven types of cancer, calling for cancer warning labels on alcohol.

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

It's been an excellent year for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech company. Viking Therapeutics' leading candidate, VK2735, is a potential GLP-1 weight loss medicine. It reported ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Crucially, the top-line reduction differed very little from the weight loss seen with Eli Lilly's combined GIP/GLP-1 agonist Zepbound (tirzepatide) at 72 weeks in the SURMOUNT-1 study, which was a ...

Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US. In a new white paper from the World Without ...

The United States' top government doctor on Friday called for health warnings on alcoholic drinks to highlight that they ...